ArticleKidney international reports2026
Sodium-Glucose Cotransporter-2-inhibitors in Adult Patients With Alport Syndrome.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Probable autosomal dominant Alport syndrome associated with a novel COL4A4 variant: A case report.Molecular genetics and metabolism reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alport syndrome (AS) is a genetically heterogenous kidney disease characterized by microhematuria, proteinuria, and progressive chronic kidney disease (CKD). Although early renin-angiotensin system inhibitors (RASi) are standard of care, evidence on sodium-glucose cotransporter-2 inhibitors (SGLT2i) in AS is limited. Thus, this study evaluated SGLT2i effects in adult patients with AS. Methods: We conducted a retrospective, observational study, including patients with genetically confirmed AS with significant proteinuria treated with combined RASi + SGLT2i. Clinico-laboratory data were collected longitudinally and compared with the preceding decade on stable RASi alone. Chronic estimated glomerular filtration rate (eGFR) and proteinuria slopes, changes in time-averaged proteinuria, subgroups responses, and secondary SGLT2i effects were assessed. Results: Eighteen adult patients with AS (mean age: 54.3 ± 15.4 years; baseline eGFR: 61.9 ± 26.5 ml/min per 1.73 m Conclusion: This real-world study suggests a potential nephroprotective role of SGLT2i in adult patients with AS, including heterozygous
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.